JP2008522162A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008522162A5 JP2008522162A5 JP2007543518A JP2007543518A JP2008522162A5 JP 2008522162 A5 JP2008522162 A5 JP 2008522162A5 JP 2007543518 A JP2007543518 A JP 2007543518A JP 2007543518 A JP2007543518 A JP 2007543518A JP 2008522162 A5 JP2008522162 A5 JP 2008522162A5
- Authority
- JP
- Japan
- Prior art keywords
- mer
- molecular weight
- tyrosine kinase
- receptor tyrosine
- transmembrane receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 24
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 24
- 102000027257 transmembrane receptors Human genes 0.000 claims 24
- 108091008578 transmembrane receptors Proteins 0.000 claims 24
- 238000000034 method Methods 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 11
- 238000012986 modification Methods 0.000 claims 10
- 230000004048 modification Effects 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 7
- 102000037865 fusion proteins Human genes 0.000 claims 7
- 108020001507 fusion proteins Proteins 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 206010053567 Coagulopathies Diseases 0.000 claims 5
- 210000000628 antibody-producing cell Anatomy 0.000 claims 4
- 208000015294 blood coagulation disease Diseases 0.000 claims 4
- 230000009852 coagulant defect Effects 0.000 claims 4
- 230000015271 coagulation Effects 0.000 claims 4
- 238000005345 coagulation Methods 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 101150022345 GAS6 gene Proteins 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 229940096437 Protein S Drugs 0.000 claims 2
- 102000029301 Protein S Human genes 0.000 claims 2
- 108010066124 Protein S Proteins 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 230000007928 solubilization Effects 0.000 claims 2
- 238000005063 solubilization Methods 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 230000023555 blood coagulation Effects 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63019204P | 2004-11-24 | 2004-11-24 | |
| PCT/US2005/042724 WO2006058202A2 (en) | 2004-11-24 | 2005-11-23 | Mer diagnostic and therapeutic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008522162A JP2008522162A (ja) | 2008-06-26 |
| JP2008522162A5 true JP2008522162A5 (enExample) | 2009-01-15 |
Family
ID=36498546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007543518A Pending JP2008522162A (ja) | 2004-11-24 | 2005-11-23 | Ｍｅｒの診断用および治療用の作用薬 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20080267975A1 (enExample) |
| EP (1) | EP1825005B1 (enExample) |
| JP (1) | JP2008522162A (enExample) |
| CA (1) | CA2630475A1 (enExample) |
| WO (1) | WO2006058202A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1710243A4 (en) * | 2004-01-29 | 2009-09-23 | Asahi Kasei Pharma Corp | THERAPEUTIC AGENT FOR VASOSPASM ACCOMPANYING A BRIDGE OPERATION |
| US8168415B2 (en) | 2007-02-07 | 2012-05-01 | The Regents Of The University Of Colorado | Axl fusion proteins as Axl tyrosine kinase inhibitors |
| AU2011207381B2 (en) | 2010-01-22 | 2016-06-09 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL signaling in anti-metastatic therapy |
| WO2012149018A1 (en) * | 2011-04-25 | 2012-11-01 | The Regents Of The University Of Colorado | Mer tyrosine kinase inhibitors and methods of making and using the same |
| US9879061B2 (en) | 2011-12-15 | 2018-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis |
| ES2862335T3 (es) | 2012-12-14 | 2021-10-07 | Univ Leland Stanford Junior | Péptidos de AXL modificados y su uso en la inhibición de la señalización de AXL en terapia anti-metastásica |
| KR20150040766A (ko) * | 2013-10-07 | 2015-04-15 | 이화여자대학교 산학협력단 | 항염증 물질을 스크리닝하는 방법 |
| CA2909669C (en) | 2014-10-20 | 2023-12-12 | Ruga Corporation | Antiviral activity of gas6 inhibitor |
| CA2972048C (en) * | 2014-12-22 | 2023-03-07 | The Rockefeller University | Anti-mertk agonistic antibodies and uses thereof |
| CA3068672A1 (en) | 2017-06-28 | 2019-01-03 | The Rockefeller University | Anti-mertk agonistic antibody-drug conjugates and uses thereof |
| EP4072680A1 (en) | 2019-12-13 | 2022-10-19 | Alector LLC | Anti-mertk antibodies and methods of use thereof |
| CN111812014B (zh) * | 2020-08-05 | 2023-04-18 | 上海市血液中心 | 一种基于纳米材料的血小板抗体检测方法和血小板保存方法 |
| EP4355786A1 (en) | 2021-06-16 | 2024-04-24 | Alector LLC | Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof |
| EP4355783A1 (en) | 2021-06-16 | 2024-04-24 | Alector LLC | Monovalent anti-mertk antibodies and methods of use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US6018026A (en) * | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
| US5554601A (en) * | 1993-11-05 | 1996-09-10 | University Of Florida | Methods for neuroprotection |
| US5585269A (en) * | 1994-06-02 | 1996-12-17 | The University Of North Carolina At Chapel Hill | Isolated DNA encoding c-mer protooncogene |
| US7339033B2 (en) * | 1998-06-26 | 2008-03-04 | Genentech, Inc. | Pro1481 |
| WO2001078778A1 (en) * | 2000-04-13 | 2001-10-25 | Vlaams Interuniversitair Instituut Voor Biotechnologie (Vib) | USE OF INHIBITION OF A Gas6 FUNCTION OR OF A Gas6 RECEPTOR FOR PREVENTING AND TREATING A CARDIOVASCULAR DISEASE |
| US20040018513A1 (en) * | 2002-03-22 | 2004-01-29 | Downing James R | Classification and prognosis prediction of acute lymphoblastic leukemia by gene expression profiling |
| WO2004029209A2 (en) * | 2002-09-24 | 2004-04-08 | Centocor, Inc. | Epitope-tagged recombinant growth arrest specific gene 6 protein |
-
2005
- 2005-11-23 EP EP05852182.4A patent/EP1825005B1/en not_active Expired - Lifetime
- 2005-11-23 WO PCT/US2005/042724 patent/WO2006058202A2/en not_active Ceased
- 2005-11-23 US US11/720,185 patent/US20080267975A1/en not_active Abandoned
- 2005-11-23 JP JP2007543518A patent/JP2008522162A/ja active Pending
- 2005-11-23 CA CA002630475A patent/CA2630475A1/en not_active Abandoned
-
2011
- 2011-09-12 US US13/230,005 patent/US20120135424A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022104941A (ja) | ヒト化抗ｃｄ７３抗体 | |
| JP2008522162A5 (enExample) | ||
| Roth et al. | Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis | |
| Bailly et al. | Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration | |
| Wright et al. | The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans | |
| TW438809B (en) | Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation | |
| Shisler et al. | The adenovirus E3-10.4 K/14.5 K complex mediates loss of cell surface Fas (CD95) and resistance to Fas-induced apoptosis | |
| JP6901493B2 (ja) | 抗ｂｃｍａポリペプチド及びタンパク質 | |
| Aluvihare et al. | Acceleration of intracellular targeting of antigen by the B‐cell antigen receptor: importance depends on the nature of the antigen–antibody interaction | |
| KR0178024B1 (ko) | 세포간 점착 분자 icam-1의 가용성 단편을 포함하는 항-바이러스제 및 이를 사용한 진단 방법 | |
| KR20190132655A (ko) | T 세포 수용체, 및 이를 사용하는 흑색종의 우선적 발현 항원(prame) 양성 암에 대한 면역 요법 | |
| Toto et al. | Immune modulation in pemphigus vulgaris: role of CD28 and IL-10 | |
| CN103459595B (zh) | 针对人前列腺素e2受体ep4的抗体 | |
| HU229417B1 (hu) | Egy tumornekrózis faktorral rokon apoptózis-indikáló ligandum receptorára specifikus antitest és alkalmazásai | |
| CN111148514A (zh) | 与免疫调节剂联合应用于癌症免疫治疗的rar选择性激动剂 | |
| JP2013520171A (ja) | Ｗｎｔシグナル伝達経路を阻害するモノクローナル抗体ならびにその製造方法およびその使用方法 | |
| CA2926944A1 (en) | Use of semaphorin-4d binding molecules for treatment of atherosclerosis | |
| KR20140054238A (ko) | 인테그린 알파-v 베타-8에 결합하는 항체 | |
| Yard et al. | Decreased glomerular expression of agrin in diabetic nephropathy and podocytes, cultured in high glucose medium | |
| Sun et al. | Contributions of the extracellular and cytoplasmic domains of platelet-endothelial cell adhesion molecule-1 (PECAM-1/CD31) in regulating cell-cell localization | |
| Horváth et al. | IgA autoantibodies in the pemphigoids and linear IgA bullous dermatosis | |
| Jafri et al. | Cholangiocyte expression of α2β1-integrin confers susceptibility to rotavirus-induced experimental biliary atresia | |
| AU2024259780A1 (en) | Peptide vaccines and pembrolizumab for treating breast cancer | |
| KR20240112996A (ko) | Hpv16 e7 항원을 인식하는 결합 단백질 및 이의 용도 | |
| Chang | Molecular mechanism of ATP-dependent solute transport by multidrug resistance-associated protein 1 |